March 14, 2019

Melucci v. Corcept Therapeutics Incorporated et al

View recent docket activity


Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.


Coverage

  1. April 12, 2023

    Corcept Inks $14M Investor Deal Over Off-Label Drug Sales

    Corcept Therapeutics Inc. has reached a $14 million settlement to end securities fraud litigation related to ifs mifepristone drug Korlym in a deal that includes a potential 25% cut for the investor plaintiffs' lawyers, according to a Monday filing in San Francisco federal court.


Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS